EUR 0.0
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 7.58 Million EUR | 227.14% |
2022 | 2.31 Million EUR | -82.2% |
2021 | 13.02 Million EUR | -18.67% |
2020 | 16.01 Million EUR | 43.34% |
2019 | 11.17 Million EUR | -10.36% |
2018 | 12.46 Million EUR | 1.06% |
2017 | 12.33 Million EUR | -3.63% |
2016 | 12.79 Million EUR | 4.7% |
2015 | 12.22 Million EUR | 117.32% |
2014 | 5.62 Million EUR | 39.09% |
2013 | 4.04 Million EUR | 10.43% |
2012 | 3.66 Million EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 1.58 Million EUR | 0.0% |
2024 Q1 | 1.58 Million EUR | -4.73% |
2023 Q4 | 1.65 Million EUR | -1.07% |
2023 Q2 | 4.16 Million EUR | -59.01% |
2023 FY | 7.34 Million EUR | 217.0% |
2023 Q1 | 10.16 Million EUR | 925.33% |
2023 Q3 | 1.67 Million EUR | -59.74% |
2022 Q2 | 4.24 Million EUR | 0.0% |
2022 Q4 | 990.99 Thousand EUR | 0.0% |
2022 FY | 2.31 Million EUR | -82.2% |
2022 Q3 | 990.99 Thousand EUR | -76.64% |
2021 Q2 | 6.43 Million EUR | 0.0% |
2021 FY | 13.02 Million EUR | -18.67% |
2021 Q4 | 8.2 Million EUR | 0.0% |
2020 Q2 | 9.78 Million EUR | 0.0% |
2020 Q4 | 8.54 Million EUR | 0.0% |
2020 FY | 16.01 Million EUR | 43.34% |
2019 FY | 11.17 Million EUR | -10.36% |
2019 Q2 | 6.72 Million EUR | 0.0% |
2019 Q4 | 7.01 Million EUR | 0.0% |
2018 Q4 | 8.29 Million EUR | 0.0% |
2018 FY | 12.46 Million EUR | 1.06% |
2017 FY | 12.33 Million EUR | -3.63% |
2016 FY | 12.79 Million EUR | 4.7% |
2015 FY | 12.22 Million EUR | 117.32% |
2014 Q3 | 1.08 Million EUR | 0.0% |
2014 Q4 | 1.88 Million EUR | 73.75% |
2014 FY | 5.62 Million EUR | 39.09% |
2013 Q4 | 1.31 Million EUR | 0.0% |
2013 FY | 4.04 Million EUR | 10.43% |
2012 FY | 3.66 Million EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Boiron SA | 317.27 Million EUR | 97.61% |
Laboratorios Farmaceuticos Rovi, S.A. | 263.09 Million EUR | 97.118% |
Vetoquinol SA | 217.11 Million EUR | 96.507% |
Valneva SE | 134.92 Million EUR | 94.38% |
AB Science S.A. | 14.01 Million EUR | 45.898% |
Nanobiotix S.A. | 62.98 Million EUR | 87.961% |
PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 69.651% |
Vivoryon Therapeutics N.V. | 24.69 Million EUR | 69.29% |
ABIVAX Société Anonyme | 127.37 Million EUR | 94.047% |
Formycon AG | 23.73 Million EUR | 68.049% |